Long-Term Efficacy of OROS® Hydromorphone Combined with Pregabalin for Chronic Non-Cancer Neuropathic Pain
Authors:
- 25 February 2014
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 34 (5) , 309-316
Abstract
Treatment for chronic non-cancer neuropathic pain can be complicated by side effects and drug interactions. Combining opioid analgesics and calcium channel modulators may overcome these and improve efficacy. The objective of the present study was to evaluate the efficacy and safety of OROS® hydromorphone combined with pregabalin in patients with chronic non-cancer neuropathic pain. This retrospective observational study was conducted on clinical records from patients aged ≥18 years with chronic non-cancer neuropathic [>4 on the Douleur Neuropathique en 4 questions (DN4) scale] pain of ≥6 months duration, with severe intensity [>4 on the Numerical Rating Scale (NRS); range 0–10], who attended all visits and had ≥12 months of follow-up at the Tor Vergata University Polyclinic Hospital, from November 2008 to February 2011. Patients received an oral combination of OROS® hydromorphone and pregabalin. Pain was evaluated at each visit (months 1, 3, 6, 9, and 12) using the NRS and DN4 scale; Patients’ Global Impression of Change (PGIC) was administered at months 1, 6, and 12. Dosage and side effects were recorded at each visit. Of 1,292 patients (32 % men, mean ± SD age 67.6 ± 11.9 years), 1,126 attended all visits. Seventeen percent (n = 224) had purely neuropathic pain. Initial mean dosage was 6.06 ± 2.00 mg/day for OROS® hydromorphone, 113.02 ± 21.94 mg/day for pregabalin. Dosages increased up to month 6, and returned to near initial dosages at month 12 (range 4–120 mg/day for OROS® hydromorphone; 75–600 mg/day for pregabalin). NRS pain scores (mean ± standard deviation) were 7.25 ± 1.34 at baseline and 1.85 ± 1.36 at 12 months (p < 0.0001); DN4 scores were 6.19 ± 1.65 at baseline, reduced to 1.84 ± 1.25 at 12 months (p < 0.0001), reductions of 74.4 and 70.2 %, respectively. More than 90 % of patients had a ≥50 % score reduction on both scales after 12 months. The PGIC scale showed that >75 % of patients felt improvement at 1 month, increasing to 91 % and 93 % at 6 and 12 months. The incidence of side effects was similar between elderly (aged >65 years) and younger subjects; there were no cases of addiction. The OROS® hydromorphone and pregabalin combination was efficacious for chronic non-cancer neuropathic pain and well tolerated, providing significant pain reduction without the risk of addiction and with a good tolerability profile, regardless of age.Keywords
This publication has 28 references indexed in Scilit:
- Antineuropathic and Antinociceptive Drugs Combination in Patients with Chronic Low Back Pain: A Systematic ReviewPain Research and Treatment, 2012
- Long-Term Controlled-Release Oxycodone and Pregabalin in the Treatment of Non-Cancer Pain: An Observational StudyEuropean Neurology, 2011
- Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impactCurrent Medical Research and Opinion, 2010
- A Randomized, Controlled Trial of Oxycodone Versus Placebo in Patients With PostHerpetic Neuralgia and Painful Diabetic Neuropathy Treated With PregabalinThe Journal of Pain, 2010
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- Use of Hydromorphone, with Particular Reference to the OROS® Formulation, in the ElderlyDrugs & Aging, 2010
- OROS® Hydromorphone Prolonged ReleaseCNS Drugs, 2010
- From Randomized Controlled Trials to Observational StudiesThe American Journal of Medicine, 2009
- Treatment of painful neuropathyCurrent Opinion in Neurology, 2007
- Opioids in renal failure and dialysis patientsJournal of Pain and Symptom Management, 2004